Andrew Spaventa - 16 Nov 2023 Form 4 Insider Report for Singular Genomics Systems, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Dalen Meeter, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 16 Nov 2023
Net transactions value: +$49,612
Form type: 4
Filing time: 20 Nov 2023, 16:31:38 UTC
Previous filing: 15 Sep 2023
Next filing: 18 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OMIC	Common Stock	Purchase	$17,857	+43,468	+1.1%	$0.4108	3,986,206	16 Nov 2023	By The Andrew K. Spaventa Living Trust dated April 9, 2014	F1
transaction	OMIC	Common Stock	Purchase	$31,755	+75,000	+1.9%	$0.4234	4,061,206	17 Nov 2023	By The Andrew K. Spaventa Living Trust dated April 9, 2014	F2
holding	OMIC	Common Stock						9,766	16 Nov 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.3770 to $0.4200, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.4200 to $0.4456, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.3770 to $0.4200, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.4200 to $0.4456, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.